Report Library
All ReportsDatamonitor Healthcare Trends & Market Access: Big Pharma Licensing Trends, 2014–18
August 20, 2019
An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in
partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer
set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more,
roughly 25%.
This Datamonitor Healthcare report contains a Trends & Market Access module.
This Datamonitor Healthcare report contains a Trends & Market Access module.
Disease Group Covered: |
Allergy
Autoimmune/immunology Cardiovascular Dermatology Endocrine ENT/Dental Gastroenterology (Non Inflammatory Bowel Disease) Hematology Infectious Disease Metabolic Neurology Not Specified Obstetrics/Gynecology Oncology Ophthalmology Orthopedics Psychiatry Renal Respiratory Rheumatology (Non Autoimmune) Urology |